IVL market projected to nearly triple by 2032

By AI, Created 10:06 AM UTC, June 03, 2026, /AGP/ – The intravascular lithotripsy market is forecast to grow from $1.04 billion in 2025 to $2.84 billion by 2032 as demand rises for minimally invasive treatment of calcified coronary and peripheral lesions. North America leads adoption now, while Asia Pacific is expected to post strong growth as healthcare access and cardiac-care investment expand.

Why it matters: - Intravascular lithotripsy is becoming a key tool for treating complex calcified artery disease without open surgery. - Rising cardiovascular disease rates and aging populations are pushing hospitals to adopt advanced catheter-based procedures. - The market is projected to grow from US$1,036.2 million in 2025 to US$2,837.7 million by 2032, signaling strong commercial and clinical demand.

What happened: - Persistence Market Research said the global intravascular lithotripsy market is set for robust expansion through 2032. - The report projects a 15.5% compound annual growth rate from 2025 to 2032. - IVL uses sonic pressure waves to break calcium deposits inside arteries and help prepare vessels before stent placement. - Coronary interventions remain the leading application segment. - Hospitals are the largest end user segment.

The details: - The report links growth to increasing cases of coronary artery disease, more elderly patients, and broader awareness of advanced vascular procedures. - Safer interventional procedures, higher hospital spending on cardiac care, and innovation in catheter-based systems are also supporting demand. - Peripheral vascular applications are growing as physicians look for safer plaque-modification technologies. - Specialty cardiac centers are adopting IVL as patient volumes rise and procedures become more efficient. - North America leads the market because of advanced healthcare infrastructure, strong reimbursement frameworks, and early adoption of new technology. - Asia Pacific is expected to expand quickly because of rising healthcare investment, better access to specialized cardiovascular treatment, and growing awareness. - High device costs and limited availability in developing markets remain major restraints. - Physician training programs, new technology, and broader healthcare investment are creating additional opportunities.

Between the lines: - The forecast points to IVL moving from a niche treatment for difficult calcified lesions toward a more established part of cardiovascular care. - The split between strong North American adoption and faster growth in Asia Pacific suggests the market is still early in its global rollout. - The cost barrier could slow penetration in lower-resource health systems even as clinical demand grows.

What’s next: - Hospitals and cardiac centers are likely to keep expanding IVL adoption as more patients need minimally invasive treatment for calcified lesions. - Market growth will likely depend on device affordability, reimbursement support, and continued physician training. - The report identifies Shockwave Medical, Boston Scientific, Medtronic, Abbott Laboratories, Terumo, and Philips Healthcare as key players in the market. - More information is available in the report sample, customization request, and full report checkout.

The bottom line: - IVL is emerging as a fast-growing segment in cardiovascular intervention, with coronary use driving near-term revenue and global expansion still uneven by region.